Table 5.
Respondents’ preferences for allocating resources when treatment costs are four times greater for rare disease compared with common disease, by survey scenario
| Scenario | No randomised to scenario | % (95% CI) | ||
|---|---|---|---|---|
| Prioritise rare disease | Prioritise common disease | Indifferent | ||
| No information | 258 | 13.2 (9.0 to 17.3) | 33.7 (27.9 to 39.5) | 53.1 (46.0 to 59.2) |
| Severe disease, high benefit | 256 | 7.0 (3.9 to 10.2) | 45.3 (39.2 to 51.4) | 47.7 (41.5 to 53.8) |
| Severe disease, low benefit | 257 | 5.8 (3.0 to 8.7) | 42.0 (36.0 to 48.1) | 52.1 (46.0 to 58.3) |
| Moderate disease, high benefit | 258 | 7.4 (4.2 to 10.6) | 45.3 (39.2 to 51.4) | 47.3 (41.2 to 53.4) |
| Moderate disease, low benefit | 260 | 6.9 (3.8 to 10.0) | 45.0 (38.9 to 51.1) | 48.1 (42.0 to 54.2) |
| Fixed funds (severe disease, high benefit) | 258 | 3.9 (1.5 to 6.2) | 60.5 (54.5 to 66.4) | 35.7 (29.8 to 41.5) |
| All scenarios | 1547 | 7.4 (6.1 to 8.7) | 45.3 (42.8 to47.8) | 47.3 (44.8 to 49.8) |